Sales, profits increase for Dr. Reddy's in Q2

HYDERABAD, India — Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

The Indian generic drug maker said the second-quarter sales represented a 21% increase over second quarter 2011. Sales from global generics were $329 million for the quarter, an 18% increase over second quarter 2011, driven mostly by growth in North America and Russia.

Profits for the quarter were $63 million, a 7% increase over second quarter 2011.

Other highlights during the quarter included 28 new generic product launches and 17 regulatory filings, as well as the Food and Drug Administration's approval of its generic version of Eli Lilly's schizophrenia and bipolar disorder drug Zyprexa (olanzapine).


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Comments

Zyprexa issues continue PTSD

Zyprexa issues continue

PTSD treatment for Veterans found ineffective.
Eli Lilly Zyprexa Olanzapine.

The use of powerful antipsychotic drugs has increased in children as young as three years old. Weight gain, increases in triglyceride levels and associated risks for diabetes and cardiovascular disease. The average weight gain (adults) over the 12 week study period was the highest for Zyprexa—17 pounds. You’d be hard pressed to gain that kind of weight sport-eating your way through the holidays.One in 145 adults died in clinical trials of those taking the antipsychotic drug Zyprexa.
This was Lilly's # 1 product over $ 4 billion per year sales,moreover Lilly also make billions on drugs that treat the diabetes often that has been caused by the zyprexa!
--- Daniel Haszard Zyprexa victim activist and patient who got diabetes from it.
http://www.zyprexa-victims.com